Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
| ▸ | SPR | P35270 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | USP19 | O94966 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838258 | 1.00 | HRH3 (0.38) | HRH3ALDH1A1MEN1KMT2AMGLL | |
| SCHEMBL18838281 | 1.00 | HRH3 (0.38) | HRH3ALDH1A1MEN1KMT2AMGLL | |
| SCHEMBL18838309 | 1.00 | HRH3 (0.38) | HRH3ALDH1A1MEN1KMT2AMGLL | |
| SCHEMBL18838305 | 1.00 | HRH3 (0.38) | HRH3ALDH1A1MEN1KMT2AMGLL | |
| SCHEMBL18838289 | 1.00 | HRH3 (0.38) | HRH3ALDH1A1MEN1KMT2AMGLL | |
| SCHEMBL18838285 | 0.89 | HRH3 (0.33) | HRH3ALDH1A1MGLLPOLBIDH1 | |
| SCHEMBL18838308 | 0.89 | HRH3 (0.33) | HRH3ALDH1A1MGLLPOLBIDH1 | |
| SCHEMBL18838259 | 0.89 | HRH3 (0.33) | HRH3ALDH1A1MGLLPOLBIDH1 | |
| SCHEMBL18838311 | 0.89 | HRH3 (0.33) | HRH3ALDH1A1MGLLPOLBIDH1 | |
| SCHEMBL18838291 | 0.89 | HRH3 (0.33) | HRH3ALDH1A1MGLLPOLBIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3340988-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | Afasci, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | HRH3 1744/4885ALDH1A1 2756/4885MEN1 2540/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | HRH3 1744/4885ALDH1A1 2756/4885MEN1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.